US Stock MarketDetailed Quotes
PCRX Pacira BioSciences
- 16.630
- -0.060-0.36%
Close Oct 16 16:00 ET
- 16.630
- 0.0000.00%
Post 16:00 ET
767.09MMarket Cap12.41P/E (TTM)
16.930High16.560Low389.17KVolume16.760Open16.690Pre Close6.48MTurnover0.85%Turnover Ratio18.69P/E (Static)46.13MShares35.95052wk High0.87P/B758.78MFloat Cap11.16452wk Low--Dividend TTM45.63MShs Float121.950Historical High--Div YieldTTM2.22%Amplitude6.160Historical Low16.663Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Pacira BioSciences Stock Forum
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...
No comment yet